These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6185813)

  • 1. In vivo and in vitro studies with agents that cause quasi-morphine withdrawal syndromes.
    Sheldon RJ; Cowan A
    Life Sci; 1982 Oct 18-25; 31(16-17):1699-702. PubMed ID: 6185813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome.
    Grant SJ; Redmond DE
    Pharmacol Biochem Behav; 1982 Oct; 17(4):655-8. PubMed ID: 6184732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of neonatal exposure to isobutylmethylxanthine. II. Attenuation of acute morphine withdrawal in mature rats.
    Neal BS; Messing RB; Sparber SB
    Psychopharmacology (Berl); 1991; 103(3):398-406. PubMed ID: 1711704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RX 336-M, a new chemical tool in the analysis of the quasi-morphine withdrawal syndrome.
    Cowan A
    Fed Proc; 1981 Apr; 40(5):1497-501. PubMed ID: 6783443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines.
    Collier HO; Cuthbert NJ; Francis DL
    Fed Proc; 1981 Apr; 40(5):1513-8. PubMed ID: 6163662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of quasi-morphine withdrawal with serotonin agonists and antagonists: evidence for a role of serotonin in the expression of opiate withdrawal.
    Kleven MS; Sparber SB
    Psychopharmacology (Berl); 1989; 98(2):231-5. PubMed ID: 2474176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine blocks and naloxone enhances suppression of operant behavior by low doses of 3-isobutyl-1-methylxanthine.
    Kleven MS; Sparber SB
    J Pharmacol Exp Ther; 1989 Jan; 248(1):273-7. PubMed ID: 2464058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of morphine withdrawal and quasi-abstinence syndrome in a model of chronic pain in the rat.
    Lérida M; Sánchez-Blázquez P; Garzón J
    Neurosci Lett; 1987 Oct; 81(1-2):155-8. PubMed ID: 3696464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serotonin2 antagonist ritanserin blocks quasi-morphine withdrawal at a time when mianserin is no longer effective.
    Neal BS; Sparber SB
    Psychopharmacology (Berl); 1990; 100(2):258-66. PubMed ID: 1689501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice.
    Bilbao A; Cippitelli A; Martín AB; Granado N; Ortiz O; Bezard E; Chen JF; Navarro M; Rodríguez de Fonseca F; Moratalla R
    Psychopharmacology (Berl); 2006 Apr; 185(2):160-8. PubMed ID: 16470403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age- and sex-related induction of excessive grooming and "wet-dog" shakes by the codeinone RX 336-M in the rat.
    Isaacson RL; Hardy CA; Hannigan JH
    Behav Neural Biol; 1987 May; 47(3):250-61. PubMed ID: 3606527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of isobutylmethylxanthine-induced suppression of operant behavior by pretreatment of rats with clonidine.
    Kleven MS; Sparber SB
    Pharmacol Biochem Behav; 1987 Oct; 28(2):235-41. PubMed ID: 2446338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Isobutyl-1-methylxanthine inhibits basal mu-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice.
    Wang Z; Bilsky EJ; Wang D; Porreca F; Sadée W
    Eur J Pharmacol; 1999 Apr; 371(1):1-9. PubMed ID: 10355588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of central serotoninergic neurotransmission in the morphine abstinence syndrome in rats.
    Kruszewska A; Langwiński R
    Drug Alcohol Depend; 1983 Nov; 12(3):273-8. PubMed ID: 6317324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal capsaicin modifies morphine withdrawal signs in the rat.
    Sharpe LG; Jaffe JH
    Neurosci Lett; 1986 Nov; 71(2):213-8. PubMed ID: 2431361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance and withdrawal to chronic morphine treatment in the week-old rat pup.
    Barr GA; Wang S
    Eur J Pharmacol; 1992 Apr; 215(1):35-42. PubMed ID: 1516648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The physical dependence liabilities of oxybutynin and morphine in rats.
    Algate DR; Beard DJ
    Arzneimittelforschung; 1985; 35(10):1577-9. PubMed ID: 4074417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACTH-(1-24) and RX 336-M induce excessive grooming in rats through different mechanisms.
    Gmerek DE; Cowan A
    Eur J Pharmacol; 1983 Apr; 88(4):339-46. PubMed ID: 6305675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
    Windh RT; Little PJ; Kuhn CM
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of quasi-morphine withdrawal behaviour induced by methylxanthines.
    Butt NM; Collier HO; Cuthbert NJ; Francis DL; Saeed SA
    Eur J Pharmacol; 1979 Feb; 53(4):375-8. PubMed ID: 217699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.